{"id":4292,"date":"2024-05-22T17:03:46","date_gmt":"2024-05-22T14:03:46","guid":{"rendered":"https:\/\/staging.iasispharma.com\/en\/?p=4292"},"modified":"2026-10-30T13:29:44","modified_gmt":"2026-10-30T11:29:44","slug":"new-product-launching-rosuzet","status":"publish","type":"post","link":"https:\/\/iasispharma.com\/en\/all-articles\/new-product-launching-rosuzet\/","title":{"rendered":"NEW PRODUCT LAUNCHING: RosuZet\u00ae"},"content":{"rendered":"<p><strong>IASIS PHARMA<\/strong> is pleased to announce the <strong>RosuZet\u00ae<\/strong> launching, in the formulation of film-coated tablets.<\/p>\n<p><strong>RosuZet\u00ae<\/strong> is the fixed dose combination of Rosuvastatin &#8211; Ezetimibe, two active ingredients that reduce serum lipid levels with complementary mechanisms of action. <strong>Pharmacotherapeutic Class:<\/strong> Lipid Modifying Agents, HMG CoA reductase inhibitors in combination with other lipid modifying agents.<\/p>\n<p><strong>RosuZet\u00ae<\/strong> is indicated as an adjunct therapy to the diet for the <strong>treatment of primary hypercholesterolemia<\/strong> for adult patients adequately controlled with the drugs administered individually at the same dose level.<\/p>\n<p><strong>RosuZet\u00ae<\/strong>, as a fixed dose combination is indicated to <strong>reduce the risk of cardiovascular events<\/strong> as therapy for patients with <strong>coronary heart disease (CHD)<\/strong> and <strong>history of acute coronary syndrome (ACS)<\/strong>, who are adequately controlled with individual agents administerted individually at the same dose.<\/p>\n<p>It is available in packs of 30 film-coated tablets and in a wide dosage range:<\/p>\n<ul>\n<li><strong>RosuZet<\/strong><strong>\u00ae<\/strong> F.C.TAB (5+10)mg<\/li>\n<li><strong>RosuZet<\/strong><strong>\u00ae<\/strong> F.C.TAB (10+10)mg<\/li>\n<li><strong>RosuZet<\/strong><strong>\u00ae<\/strong> F.C.TAB (20+10)mg<\/li>\n<li><strong>RosuZet<\/strong><strong>\u00ae<\/strong> F.C.TAB (40+10)mg<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>IASIS PHARMA is pleased to announce the RosuZet\u00ae launching, in the formulation of film-coated tablets. RosuZet\u00ae is the fixed dose combination of Rosuvastatin &#8211; Ezetimibe, two active ingredients that reduce serum lipid levels with complementary mechanisms of action. Pharmacotherapeutic Class: Lipid Modifying Agents, HMG CoA reductase inhibitors in combination with other lipid modifying agents. RosuZet\u00ae  [&#8230;]<\/p>\n","protected":false},"author":3,"featured_media":4278,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[33,145,146],"tags":[],"class_list":["post-4292","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-articles","category-company-news","category-product-launches"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7HJeP-17e","jetpack_featured_media_url":"https:\/\/iasispharma.com\/wp-content\/uploads\/2024\/05\/pack-shot-Rosuzet-X-4-copy.png","_links":{"self":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts\/4292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/comments?post=4292"}],"version-history":[{"count":1,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts\/4292\/revisions"}],"predecessor-version":[{"id":4293,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/posts\/4292\/revisions\/4293"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/media\/4278"}],"wp:attachment":[{"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/media?parent=4292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/categories?post=4292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/iasispharma.com\/en\/wp-json\/wp\/v2\/tags?post=4292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}